Intellia Therapeutics (NASDAQ:NTLA) Rating Lowered to “Sell” at Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also recently commented on NTLA. Wolfe Research reaffirmed a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. Guggenheim downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Finally, Royal Bank Of Canada lowered their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a report on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $18.43.

Intellia Therapeutics Stock Down 1.6%

Shares of NASDAQ NTLA opened at $9.44 on Friday. The business has a 50-day moving average price of $11.48 and a 200 day moving average price of $12.64. The stock has a market cap of $1.09 billion, a PE ratio of -2.21 and a beta of 2.13. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.34) earnings per share. Sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 1,871 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares in the company, valued at $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics in the third quarter valued at approximately $30,000. Blue Bell Private Wealth Management LLC purchased a new position in Intellia Therapeutics in the third quarter worth $30,000. Advisory Services Network LLC acquired a new stake in Intellia Therapeutics in the third quarter valued at $33,000. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter worth $26,000. Finally, Danske Bank A S purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $50,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.